Abstract: An extended-release antibiotic composition comprising at least one antibiotic, and greater than 50 weight percent, based on the total weight of the composition, of a polymer component, wherein said polymer component comprises at least one pharmaceutically acceptable hydrophilic polymer, and said polymer component has a viscosity of less than about 50 cps.

Abstract: A process for the preparation of polymorph Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine, or olanzapine.

Abstract: 2,5-Dichlorophenol is readily and facilely prepared from 2,5-dichloro-4-hydroxybenzenesulfonic acid or salt thereof, said sulfonic acid/sulfonate itself being characteristically produced by hydrolysis of a precursor trichlorobenzenesulfonic acid, by cleaving the sulfo/sulfonate moiety therefrom by treatment, e.g., under reflux, with a constant boiling point hydrobromic acid.

Abstract: This invention relates to a composition and method for potentiating the antidepressant effect of dibenzocycloheptadiene-type antidepressant agents, for example, nortriptyline, in the treatment of depression, especially geriatric depression, by administering them in combination with an approximately 1:1:1 by weight mixture of dihydroergocryptine (2:1 .alpha.:.beta.), dihydroergocornine and dihydroergocristine.

Abstract: Dry souffle compositions having malto/Dextrin and Zanthan gum and wherein the resulting soufflees have an improved foam structure.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are alkyl or aryl groups, A, B, C and D are non-reactive substituents or two are joined to form an additional ring, and Z is either of the formula Z': ##STR2## wherein R.sup.4 is H, lower alkyl or a cation; or a -6-oxotetrahydropyran-2-yl ring of the formula Z": ##STR3## e.g. 4-hydroxy-6-{2-[2-(methyldiphenylsilyl)phenyl]ethenyl]ethyenyl}-tetrahydro -2H-pyran-2-one, (trans, trans). The compounds inhibit cholesterol biosynthesis and are useful as anti-atherosclerotic agents.

Abstract: This disclosure relates to substituted indolamines, which exhibit anti-diabetic activity, having the formula: ##STR1## where m is an integer from 1 to 4,x represents hydrogen or --OHR represents Ar or ##STR2## and Ar represents ##STR3## R.sub.1 represents hydrogen, fluoro, chloro, lower alkyl or lower alkoxy, R.sub.2 and R.sub.3 each, independently, represent lower alkyl, orR.sub.2 and R.sub.3 together with N represent ##STR4## wherein n is 1, 2 or 3,R.sub.4 represents hydrogen or lower alkyl, andR.sub.5 represents hydrogen or lower alkyl, unsubstituted phenyl or phenyl substituted with fluoro, chloro, lower alkyl or lower alkoxy, oror pharmaceutically acceptable acid addition salts thereof.

Abstract: 6-Substituted-4-hydroxy-tetrahydropyran-2-ones, useful as anti-atherosclerotic agents, are obtainable by the process of the invention. The 6-substituents have a phenyl, naphthyl, tetrahydronaphthyl or indolyl nucleus bound through an ethenyl unit. The invention includes novel intermediates.

Abstract: Process and apparatus for the production of medicament containing liposomes, comprising an aliphatic lipid-sterol-water lamellae, wherein a clear, mixed micellar medicament-detergent-aliphatic lipid-sterol sample is applied to a gel filtration column. The column effluent is continuously monitored to detect the liposome fraction eluted, which is collected. The free medicament, detergent, lipid and/or sterol may be recirculated back to the column.

Abstract: This disclosure relates to the aspermatogenesis activity of(a) compounds of the formula: ##STR1## where m is an integer from 1 to 4X represents hydrogen or --OHR represents Ar, ##STR2## Ar represents ##STR3## R.sub.1 represents hydrogen, fluoro, chloro, lower alkyl or lower alkoxy, R.sub.2 and R.sub.3 each, independently, represent lower alkyl, orR.sub.2 and R.sub.3 together with N represent ##STR4## wherein n is 1, 2 or 3,R.sub.4 represents hydrogen or lower alkyl, andR.sub.5 represents hydrogen or lower alkyl, unsubstituted phenyl or phenyl mono- or di-substituted with fluoro, chloro, lower alkyl or lower alkoxy, or(b) compounds of the formula: ##STR5## where R' is Ar or ##STR6## Ar, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined above, or a pharmaceutically acceptable acid addition salt thereof.

Abstract: This disclosure describes novel compounds of the formula ##STR1## where m is 2, 3 or 4X is hydrogen or hydroxyR.sub.1 represents hydrogen, fluoro, chloro, lower alkyl having 1 to 4 carbon atoms or lower alkoxy having 1 to 4 carbon atoms, andR.sub.2 and R.sub.3 each independently represent lower alkyl as defined above, orR.sub.2 and R.sub.3 together with N represent ##STR2## wherein n is 1, 2 or 3, andR.sub.4 represents hydrogen or lower alkyl as defined above, andR.sub.5 represents hydrogen, lower alkyl, phenyl or phenyl substituted with fluoro, chloro, lower alkyl having 1 to 4 carbon atoms, or lower alkoxy having 1 to 4 carbon atoms, with the proviso that when X is hydroxy, m is 3 or 4,or a pharmaceutically acceptable acid addition salt thereof, which are useful in the treatment of diabetes by inhibiting or impeding post-prandial hyperglycemia.

Abstract: This disclosure relates to the aspermatogenesis activity of compounds of the following formula: ##STR1## where R.sub.1 and R.sub.2 each independently represent hydrogen, halo having an atomic weight of about 19 to 36, lower alkyl having 1 to 4 carbon atoms, lower alkoxy having 1 to 4 carbon atoms, trifluoromethyl, orR.sub.1 is ##STR2## and R.sub.2 is hydrogen, whereinR.sub.7 and R.sub.8 are each independently hydrogen or lower alkyl having 1 to 2 carbon atoms,n is 0 or 1, andR.sub.3, R.sub.4, R.sub.5 and R.sub.6 each independently represent lower alkyl having 1 to 2 carbon atoms ora pharmaceutically acceptable salt thereof.

Abstract: This disclosure describes compounds of the formula ##STR1## where R.sub.1 represents hydrogen, fluoro, chloro, lower alkyl having 1 to 4 carbon atoms or lower alkoxy having 1 to 4 carbon atoms, andR.sub.2 represents hydroxy, andR.sub.3 and R.sub.4 each independently represent lower alkyl as defined above, orR.sub.3 and R.sub.4 together with N represent ##STR2## wherein n is 1, 2 or 3, andR.sub.5 and R.sub.6 each independently represent hydrogen or lower alkyl as defined above,or a pharmaceutically acceptable acid addition salt thereof, which are useful as anti-diabetic agents, in particular as hypoglycemic agents and inhibiting or impeding post-prandial hyperglycemia.

Abstract: This invention provides for the production of microspheres in an oil-in-water emulsion process using an emulsifier, whereby solvent removal from the oil phase allows for isolation of discrete microspheres, wherein the release rate of a core material is modified by the use of an alkaline agent, e.g. sodium hydroxide, during the preparation of the microspheres.

Abstract: Single enanitiomers of 6-(2-hydrocarbyl-substituted ethenyl)-bearing, 4-hydroxy tetrahydro-2H-pyran-2-ones, e.g., 6.alpha.-[2-(2-methyl-1-naphthyl)ethenyl]-3,4,5,6-tetrahydro-4.beta.-hydro xy-2H-pyran-2-one (4R,6S) are obtained by a multi-step process which includes protecting and deprotecting hydroxy groups at various stages.

Abstract: The invention provides a method of converting ethylenically unsaturated units of an olefinic substrate to corresponding cyclopropanyl units, comprising treating the olefinic substrate, in an ether medium, with zinc and diiodomethane and a catalytic amount of a metallo-hydride reducing agent. Preferred substrates are olefinic fatty acids or their functional derivatives, e.g. oleic acid esters.

Abstract: This disclosure describes compounds of the formula ##STR1## where R.sub.1 represents hydrogen, fluoro, chloro, lower alkyl having 1 to 4 carbon atoms or lower alkoxy having 1 to 4 carbon atoms, andR.sub.2 and R.sub.3 each independently represent lower alkyl as defined above, orR.sub.2 and R.sub.3 together with N represent ##STR2## wherein n is 1, 2 or 3, andR.sub.4 and R.sub.5 each independently represent hydrogen or lower alkyl as defined above,or a pharmaceutically acceptable acid addition salt thereof, which are useful as anti-diabetic agents in particular as hypoglycemic agents and inhibiting or impeding post-prandial hyperglycemia.

Abstract: The invention relates to a new process for preparing alkoxylates containing primary amine functions comprising reacting a monoalkanolamine or a polyamine compound with a carbonyl compound to form an amide- or carbamate-type condensation product, reacting said condensation product with an alkylene oxide compound to form an alkylene oxide adduct of said condensation product, and salifying the so-formed adduct under mild, acidic conditions.

Abstract: The compounds are secondary amides of the formulaA--C.tbd.CO--NH--BwhereinA is alkyl, a mono- or poly-ethylenically unsaturated acyclic hydrocarbon chain, or a hydrocarbon chain having from 1 to 4 cyclopropanyl units thereon; andB is a radical which may be of the phenyl, benzyl, phenylalkyl, benzocycloalkyl or indol- type, e.g., N-[1-phenyl-2-(p-methylphenyl)-ethyl]-oct-2-ynoylamide.The compounds are useful as pharmaceutical agents.